Unlike an flexible savings account, health savings account funds don't expire at the end of the year and they're portable. » Read More
Investors who backed a biotech company led by Martin Shkreli are suing to get back the $5.4 million they invested just hours before his arrest.
A former researcher says the pharma giant fired him for raising red flags about statistical problems in tobacco-cessation studies.
Check out Prothena CEO Dale Schenk's revealing update on the state of the company's pipeline and its prospects.
Biotech CEOs say that drug pricing needs to be balanced enough to support research and development.
Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.
Several factors are being overlooked when discussing drug pricing in the U.S., three pharma CEOs say.
Celgene Chairman and CEO Bob Hugin, discusses his outlook for the health care industry, and M&A in the space.
Discussing research and development in the biotech space, and drug pricing responsibly, with Johnson & Johnson CEO Alex Gorsky.
Liquid biopsies that show genetic mutations of DNA in a person's blood will dramatically improve early detection of cancers.
Insight to the regulatory process of pricing drugs, with Ian Read, Pfizer Chairman and CEO.
The JPMorgan Health Care Conference, which kicks off next week, could take on a more muted tone than in previous years.
CNBC's Meg Tirrell reports the latest news in the health care sector including Shire buying Baxalta for $32 billion and the formation of a new company to develop a blood test for cancer.
The Obama administration said recently that more than 11 million have signed up for health insurance. Experts see it differently.
Updated guidelines warn that consuming any amount of alcohol increases the risk to your health.
Mount Sinai Hospital's CEO told CNBC that while Obamacare survived a repeal attempt, it's locked in a tough game of numbers.
Virtual reality is the newest tech toy, but dizziness and other side effects could derail the momentum, says Doug Magyari.
Get the best of CNBC in your inbox